Use of chimeric antigen receptor modified cells to treat autoimmune disease
Embodiments of the present disclosure include a method for treating Systemic Lupus Erythematosus (SLE) using CD19 CAR T cells. The method includes administering to the human patient a pharmaceutically effective amount of a population of T cells of the human patient that express a chimeric antigen receptor (CAR) that comprises the amino acid sequence of, e.g., SEQ ID NO: 23.
1. A method for treating Systemic Lupus Erythematosus (SLE) in a subject, the method comprising:
administering to the subject a pharmaceutically effective amount of a population of T cells expressing a chimeric antigen receptor (CAR) that binds an antigen associated with B cells, wherein the CAR comprises amino acid sequence SEQ ID NO: 18.
2. The method of claim 1 , wherein the antigen is CD19.
3. The method of claim 1 , wherein the T cells comprise amino acid sequence SEQ ID NO: 23.
4. The method of claim 3 , wherein the subject is a human patient and wherein the pharmaceutically effective amount of the population of T cells is about 10 4 to 10 9 cells per kg body weight of the human patient.
5. The method of claim 3 , wherein the subject is a human patient and wherein the pharmaceutically effective amount of the population of T cells is about 10 5 to 10 6 cells per kg body weight of the human patient.
6. The method of claim 3 , wherein the subject is a human patient and wherein the pharmaceutically effective amount of the population of T cells is about 10 6 to 10 7 cells per kg body weight of the human patient.
7. The method of claim 3 , wherein the subject is a human patient and wherein the pharmaceutically effective amount of the population of T cells is about 10 4 to 10 5 cells per kg body weight of the human patient.
8. The method of claim 3 , wherein the subject is a human patient and wherein the pharmaceutically effective amount of the population of T cells is about 10 7 to 10 8 cells per kg body weight of the human patient.
9. The method of claim 3 , wherein the subject is a human patient and wherein the pharmaceutically effective amount of the population of T cells is about 10 8 to 10 9 cells per kg body weight of the human patient.
10. The method of claim 1 , wherein the method further comprises measuring a level of: a urine protein, a serum anti-double-stranded DNA antibody, renal impairment, and/or damage to skin of the subject.
11. The method of claim 10 , wherein the level of the urine protein, the serum anti-double-stranded DNA antibody, the renal impairment, and/or the damage to the skin of the subject decreases, as compared to a control subject.